(2-(2,4-difluorophenyl)-4,5-bis(4-methoxyphenyl) imidazole) was given to rats in a single oral dose of 30 mg/kg. The plasma con centration of fenflumizole reached a peak 2-3 hr after the dosing in non-fasted as well as fasted rats. Two metabolites (demethylation products) of fenflumizole were also detected in the plasma, but only in traces. Fenflumizole (30 and 100 mg/kg) and aspirin (100 mg/kg), given orally 2 hr prior to i.v. arachidonate (80 mg/kg), were effective in protecting the rats from death. Fenflumizole in single oral doses of 100 to 800 mg/kg dose-dependently developed erosions in the rat gastric mucosa, but was much less ulcerogenic than aspirin (3.12-200 mg/kg). Thus, fenflumizole seems to possess a potent antithrombotic activity and a relatively low gastro-ulcerogenicity in rats.
During the past decades, a body of basic knowledge has developed concerning the platelet, its role in thrombosis and its potential involvement in the pathogenesis of angina pectoris, myocardial infarction, and cere brovascular disease (1) . Fenflumizole, a newly developed non-steroidal anti-inflam matory drug (2) , possesses a powerful anti platelet property in rabbits (3) and human volunteers (3) (4) (5) , and it has been considered a candidate for antiaggregatory therapy in patients.
However, this class of drugs is generally limited in their clinical application due to the high incidence of gastrointestinal ulcerations (6) . The present study in rats, therefore, was undertaken to compare further antithrombotic and ulcerogenic profiles of fenflumizole with those of aspirin, one of the currently available antiinflammatory drugs.
Male Sprague-Dawley rats, weighing 250 to 300 g, were used. Half of the animals were fasted overnight before the experiment but water was allowed ad libitum.
Pharmacokinetic study: Under light ether anesthesia, the femoral artery was cannulated with polyethylene tubing. After arterial blood (0.3 ml) was withdrawn in heparinized polyethylene centrifuge tubes, the rats were given orally fenflumizole (30 mg/kg) and kept in Bollman cages under normal housing conditions. The body temperature was main tained at 37-38°C by a heat lamp. Blood samples (0.3 ml) were taken, at different time points: 10, 20, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24 and 48 hr after drug administration. All samples were carefully protected from light. Blood was centrifuged at 6000 rpm for 2 min with a Hitachi Refrigerated Centrifuge (05PR-22). Plasma was separated and then frozen at -20°C until assayed (within one week) . The plasma concentrations of fenflumizole and the two metabolites were determined ac cording to the method of Midskov (7), with a slight modification.
Antithrombotic study: Arachidonate induced thromboembolic death was ex amined 2 hr after oral dosing of fenflumizole or aspirin. According to Kohler et al. (8) , it seems that the i.v. administration of arachido nate to animals is a useful model for inducing ** To whom correspondence should be addressed .
platelet aggregation in vivo and for evaluating platelet aggregation inhibitors and potential antithrombotic agents. The amount of arachidonate (80 mg/kg) was chosen as the minimum dose that lead to the death of all of the rats. Five % arachidonate solution was given in a volume of 160 ,ul/100 g body weight into the tail vein for 10 sec. Obser vation was made for 30 min after the finish of arachidonate solution injection. The efficacy of the tested drugs was determined as the percent decrease in mortality rate in the drug-treated group against the non treated (control) one.
Acute ulcerogenic study: The rats were housed in individual cages with a raised mesh bottom. Five hr after fenflumizole or aspirin was given by gastric incubation, the animals were anesthetized with ether. The duodenum and stomach of each animal were dissected out as a single unit, inflated by injecting 1 % formalin solution, and immersed in 1 % formalin solution for 10 min to fix the inner and outer layers. They were then opened along the opposite site of mesenteric attach ment for the duodenum and the greater curvature for the stomach and examined for ulcers. The incidence of the ulcers was determined under a dissecting microscope (10X) with a square grid. The ulcer index could not be calculated, since the erosions induced by the drugs, especially fenflumizole, appeared vari-form.
The drugs used were: 2-(2,4-difluoro phenyl) -4,5-bis (4-methoxyphenyl) imidazole, fenflumizole, and mono and di-demethyl fenflumizole (all from Dumex, Denmark) and aspirin and arachidonate sodium salt (from porcine liver approx. 90%) (both from Sigma, St. Louis, U.S.A.). Fenflumizole and aspirin were suspended in 2% gum arabic solution, and the solutions were given orally in a volume of 2 ml/kg. Sodium arachidonate was dissolved in 0.9% saline solution, just before the experiments, and the solution in a syringe was immersed in ice-cold water in order to preserve the pharmacological activity over long periods. The ED50-values for the tested drugs (doses protecting the rats from arachidonate-induced death by 50%) were estimated roughly from the dose response curves. The U D50 values (doses inducing ulcer by 50%) were calculated for determining relative potencies according to Litchfield and Wilcoxon (9). In comparing 2 sets of means, the x2-test was used. The data in the text are expressed as means±S.E. P values less than 0.05 were considered statistically significant.
The plasma concentrations of fenflumizole and the metabolites were determined after oral dosing of 30 mg/kg fenflumizole in fasted and non-fasted rats. The average maximum plasma concentrations (Cma..) of fenflumizole were 979.6±161.1 ng/ml (N=5) in fasted rats and 1335.9*348.5 ng/ ml (N=5) in non-fasted rats at 2-3 hr after dosing, and they thereafter declined pro gressively, reaching near the predose level 48 hr after dosing. The time (Tma,X) to attain the maximum concentration for fenflumizole was almost constant in fasted and non fasted preparations, even though it had a tendency to occur earlier in non-fasted rats (2.6±0. 5 hr, N=5) than in fasted ones (3.6±0. 6 hr, N=5). The metabolites of fenflumizole, mono and di-demethylated fenflumizole could also be identified in plasma, but only in traces.
Since the Tmax for fenflumizole was 2-3 hr after the dosing in non-fasted as well as fasted rats, fenflumizole (10 to 100 mg/kg) was given orally approximately 2 hr prior to i.v. arachidonate (80 mg/kg), and the effect was compared with that of aspirin (30 and 100 mg/kg) (upper part in Table 1 ). Sig nificant protection against arachidonate induced death was observed in an oral dose of 100 mg/kg of fenflurnizole and aspirin in fasted rats. On the other hand, in non-fasted rats, fenflumizole in doses of 30 and 100 mg/kg was effective in protecting the animals from the death, but aspirin was effective only in a dose of 100 mg/kg. Thus, the protecting effect of aspirin was to the same extent in fasted and non-fasted animals. However, the activity of fenflumizole in protecting the animals from the death appeared less in fasted animals than in non-fasted ones, probably reflecting the plasma concentrations.
Ulcerogenic effects and UD50-values for fenflumizole and aspirin after single oral administration are shown in the lower part of Table 1 . When fenflumizole (100-800 Table 1 . Anti-thrombotic and ulcerogenic effects of fenflumizole and aspirin given orally to rats *P<0 .05, "'"P<0.01 vs. control (X2-test). UD50/ED50=47.7 for fenflumizole and 0.14 for aspirin in fasted rats; 27.7 for fenflumizole and 1 .0 for aspirin in non-fasted rats. mg/kg) and aspirin (3.12-200 mg/kg) were given, they caused erosions in the gastric mucosa, but appreciable changes were absent in the duodenal mucosa. There was no positive observation indicating perfora tion in the gastrointestinal tract. Although the effects of these drugs appeared in a dose dependent manner, fenflumizole was much less ulcerogenic than aspirin in both the fasted and non-fasted rats.
Corell and Hasselmann (10) demonstrated in rats that the ratios between the gastro ulcerogenic dose and anti-inflammatory or anti-pyretic doses are considerably higher for fenflumizole as compared to other non steroidal anti-inflammatory drugs, and they therefore have suggested that fenflumizole is a compound with retained therapeutic activities but reduced side effects, particularly on the gastrointestinal tract. Similar results were obtained in the present experiment. As shown in the Vane (11) proposed a relationship between the production of gastric erosions and the inhibition of mucosal PG12 formation by anti-inflammatory drugs: a reduction in PG biosynthesis by aspirin-like drugs in the gastric mucosa leads to a fall in local blood flow which, in turn, gives rise to areas of focal ischemia, ultimately developing into erosions. Similar results were obtained by Whittle et al. (12) . Taking together these data into consideration, it is likely that the weak inhibition of gastric PG12 generation accounts for the weak gastro-ulcerogenicity of fenflumizole.
